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Introduction
Manganese chloride (MnCl2) rapidly releases free Mn2+ in
the blood allowing for its active intracellular uptake by
myocytes thus making it a potentially ideal candidate for
perfusion and viability studies of the myocardium. How-
ever, MnCl2 toxicity might reduce the clinical effectiveness
of the substance as a contrast agent. Therefore, we
designed this study to investigate for the first time in
humans the safety and efficacy of a rapid infusion of
MnCl2 for cardiovascular magnetic resonance (CMR)
imaging.
Methods
Fifteen normal volunteers underwent a CMR exam on a
commercial 1.5 T scanner. Before the infusion, evaluation
of cardiac function was performed with a short axis mid-
ventricular slice being chosen for the signal intensity stud-
ies. Images of this slice were obtained using a 2D and 3D
gradient-echo inversion recovery (GRE-IR) sequence, a
phase-sensitive IR sequence and a single breath-hold seg-
mented IR prepared steady-state precession acquisition
for T1 calculations. MnCl2 was infused in three minutes at
a total dose of 5 μMol/kg. Immediately after the infusion,
at 15 and 30 minutes new images were obtained and car-
diac function was re-evaluated.
Results
There was a significant decrease in T1 values compared to
baseline, sustained up to 30 minutes after the MnCl2 infu-
sion (Table 1). The 2D GRE-IR sequence showed the great-
est relative increase in signal intensity compared to the
other sequences (Figure 1). There was a slight increase in
systolic pressure and heart rate after three and four min-
utes of the infusion with normalization of these parame-
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Table 1: 
Variable Pre 0 min 15 min 30 min P
GRE-IR 2D 71 ± 11 57 ± 12 49 ± 14 < 0.0001
GRE-IR 3D 39 ± 15 59 ± 27 22 ± 8 0.02
IR-SSFP 48 ± 7 33 ± 5 42 ± 6 <0.0001
Phase Sensitive IR 10 ± 1.3 11 ± 1.6 7 ± 1.8 <0.0001
T1 (ms) 773 ± 168 653 ± 125 654 ± 125 647 ± 120 0.005
R1 (Hz) 1.35 ± 0.31 1.56 ± 0.23 1.59 ± 0.35 1.61 ± 0.37 0.03
Ejection Fraction (%) 65.7 ± 1.7 67.1 ± 1.6 66.9.0 ± 1.7 67.0 ± 1.9 0.22
Values are means ± SD.Page 1 of 2
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ters thereafter. Patients showed good tolerance to MnCl2
with no major adverse events, despite all patients report-
ing transient facial flush.
Conclusion
In the short term, MnCl2 appears safe for human use. It
effectively decreases myocardium T1, maintaining this
effect for a relatively long period of time and allowing for
the development of new imaging strategies in CMR.
2D GRE-IR image at pre-injection (A), 0 minutes after (B), 15 minutes (C) and 30 minutes (D)Figure 1
2D GRE-IR image at pre-injection (A), 0 minutes after (B), 15 minutes (C) and 30 minutes (D).Page 2 of 2
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